Financial Performance - Operating revenue for the reporting period was CNY 388,966,940.41, down 20.60% year-on-year, and CNY 1,266,419,771.74 for the year-to-date, down 24.55%[8] - Net profit attributable to shareholders was a loss of CNY 69,519,387.49, a decrease of 296.21% compared to the same period last year[8] - Basic earnings per share were negative CNY 0.2186, a decrease of 296.23% compared to the same period last year[8] - The company reported a total comprehensive loss of CNY 68,476,731.52 for the quarter, compared to a comprehensive income of CNY 37,255,905.09 in Q3 2018[49] - The company reported a total comprehensive income of ¥15,964,152.30, compared to ¥79,754,405.57 in the previous year, reflecting a significant decline[60] Cash Flow and Assets - The net cash flow from operating activities was negative CNY 32,129,991.28, a decline of 161.63% year-on-year[8] - The company’s cash and cash equivalents decreased from CNY 327,282,000 to CNY 258,034,900, mainly due to investment activities[16] - Cash and cash equivalents at the end of the period were ¥194,519,497.10, down 35.8% from ¥302,909,742.57 at the end of Q3 2018[64] - Cash flow from operating activities generated a net amount of ¥129,371,642.62, an increase of 42.4% compared to ¥90,847,545.43 in the same period last year[63] - The ending cash and cash equivalents balance was CNY 73,085,841.26, down from CNY 93,219,743.42, a decrease of approximately 21.6%[67] Liabilities and Equity - Total liabilities were CNY 1,342,174,295.50, down from CNY 1,491,996,178.18, indicating a decrease of about 10%[39] - The company's equity attributable to shareholders was CNY 3,126,435,667.64, down from CNY 3,190,269,836.62, a decline of approximately 2%[40] - Total liabilities were CNY 751,461,037.10, with current liabilities totaling CNY 589,803,293.70[77] - The total equity attributable to shareholders of the parent company reached CNY 3,190,269,836.62[76] Expenses - The company reported an increase in sales expenses from CNY 68,022,000 to CNY 129,959,700, primarily due to efforts to expand market presence[16] - Total operating costs increased to CNY 481,261,090.96, up 1.5% from CNY 476,569,014.30 year-over-year[47] - Research and development expenses were CNY 6,080,165.85, down 41.5% from CNY 10,370,990.19 in the previous year[47] - Sales expenses surged to ¥105,920,757.89, compared to ¥19,875,258.82 in Q3 2018, indicating a substantial increase in marketing efforts[59] Regulatory and Legal Issues - The company is under "delisting risk warning" due to an audit report from Beijing Xinghua Accounting Firm indicating an inability to express an opinion on the 2018 financial report[17] - The company is facing significant legal challenges, including allegations of bribery and production/sale of counterfeit drugs against key personnel[18] - The company has not fully complied with the commitment to increase shareholdings by major shareholders and former executives, with a deadline set for 180 days from the regulatory notice[18] - The company has committed to repurchase at least 1% of its total shares (3.18 million shares) within six months starting from November 8, 2018, but has not fully complied with this commitment due to ongoing judicial investigations involving key executives[22] Investments and Patents - The company received an invention patent certificate for a method of preparing aluminum-magnesium double-layer tablets[19] - The company has invested 4,000 million RMB in bank wealth management products, with the entire amount still outstanding[32] - The company reported a total of 13,202.5 million RMB in non-operating fund occupation by major shareholders, which accounts for 4.05% of the latest audited net assets[29] Shareholder Information - The total number of shareholders at the end of the reporting period was 28,351[12] - The company reported that the chairman of the supervisory board, Chen Xiaohong, and supervisor Tan Guotai planned to reduce their holdings, with Tan Guotai having reduced 40,000 shares at an average price of 5.61 yuan per share[17]
ST天圣(002872) - 2019 Q3 - 季度财报